Now You See It, Now You Do Not: A Case of Infliximab-Induced Vanishing Bile Duct Syndrome. Issue 7 (July 2019)

• Record Type: Journal Article
• Authors: Shah, Parth; Larson, Brent; Wishingrad, Marc; Nissen, Nicholas; Björnsson, Einar; Sundaram, Vinay
• Is Part Of: ACG Case Reports Journal. Volume 6:Issue 7(2019)
• Publication Date: 2019-07
• DOI: 10.14309/crj.0000000000000134
• Languages: English
• ISSNs: 2326-3253

Abstract

Abstract : ABSTRACT: Infliximab is a commonly used antitumor necrosis factor alpha agent, especially in patients with inflammatory bowel disease. It has been associated with drug-induced liver injury including immunologic reactions, with rare cases of acute liver failure. We describe a patient with chronic cholestasis and loss of intrahepatic bile ducts after therapy with infliximab for refractory ulcerative colitis consistent with a diagnosis of vanishing bile duct syndrome. About 3 months after the initial infusion, the patient developed subfulminant liver failure and required liver transplantation.